despite its dominance of the genesequencing market and its monitoring of customers’ usage of its gear illumina fell well short of the sales it had expected for its june quarter the san diego company slashed its forecast for revenue growth in 2022 to between 4 and 5 from 14 to 16 while chief executive francis desouza attributed the shortfall disclosed late thursday to macroeconomic pressures on customers supplychain delays and a drop in covid testing questions from analysts on a conference call to discuss the results evinced dissatisfaction with what he said illumina stock ticker ilmn fell 79 to 20950 in early trading on friday